Cooperative molecular motors moving back and forth

We use a two-state ratchet model to study the cooperative bidirectional motion of molecular motors on cytoskeletal tracks with randomly alternating polarities. Our model is based on a previously proposed model [Badoual et al., {\em Proc. Natl. Acad. Sci. USA} {\bf 99}, 6696 (2002)] for collective motor dynamics and, in addition, takes into account the cooperativity effect arising from the elastic tension that develops in the cytoskeletal track due to the joint action of the walking motors. We show, both computationally and analytically, that this additional cooperativity effect leads to a dramatic reduction in the characteristic reversal time of the bidirectional motion, especially in systems with a large number of motors. We also find that bidirectional motion takes place only on (almost) a-polar tracks, while on even slightly polar tracks the motion is unidirectional. We argue that the origin of these observations is the sensitive dependence of the cooperative dynamics on the difference between the number of motors typically working in and against the instantaneous direction of motion.Comment: Accepted for publication in Phys. Rev.

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

Background: Gastric carcinoid tumours type 1 (GCA1) originate from hyperplastic enterochromaffin-like (ECL) cells secondary to hypergastrinaemia. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. We conducted a multicentre prospective study to assess the effects of long-acting SSA on hypergastrinaemia and ECL-cell proliferation in patients with GCA1. Methods: We studied 15 patients with GCA1 treated with monthly long-acting release octreotide (LAR) (20-30 mg; n = 14) or Lanreotide 90 mg (n = 1) for at least 6 months. Patients had serum gastrin and chromogranin A measurements performed and biopsies taken from both tumours and surrounding mucosa before, and every 6-12 months following treatment. Sections were immunostained for neuroendocrine markers. The cell proliferation index Ki-67, intensity of staining before and after treatment and the degree of gastric wall invasion were also assessed. Results: All patients tolerated treatment well (mean follow-up of 18 months). In 11 patients (73%), a complete disappearance of the tumours at 1 year of treatment was observed on endoscopy, while in three patients (20%), the tumours decreased significantly in number and size. Gastrin levels normalized in 25% of patients, and were reduced by more than 80% in the remaining 75%. Conclusions: Treatment with SSAs in GCA1 leads to a substantial tumour load reduction, with a concomitant decrease of serum gastrin levels. Our data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. © 2008 European Society of Endocrinology